**Supplementary Table**: percentage of patients monitored at least once before and during glucocorticoid exposure according to the underlying disease and the duration of exposure

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Asthma | | COPD | | Rheumatoid arthritis | | Inflammatory bowel diseases | | Polymyalgia rheumatica/giant cell arteritis | |
|  | 3-12 months  n=9804 | > 12 months  n=1915 | 3-12 months  n=9277 | > 12 months  n=1979 | 3-12 months  n=3046 | > 12 months  n=2289 | 3-12 months  n=3910 | > 12 months  n=548 | 3-12 months  n=12643 | > 12 months  n=10099 |
| **Weight**  before exposure  during exposure | 1999 (20.4%)  2453 (25.0%) | 487 (25.4%)  1220 (63.7%) | 2082 (22.4%)  2699 (29.1%) | 452 (22.8%)  1241 (62.7%) | 588 (19.3%)  744 (24.4%) | 465 (20.3%)  1273 (55.6%) | 925 (23.7%)  955 (24.4%) | 148 (27.0%)  282 (51.5%) | 2423 (19.2%)  3628 (28.7%) | 1961 (19.4%)  5697 (56.4%) |
| **Blood pressure**  before exposure  during exposure | 3542 (36.1%)  4366 (44.5%) | 836 (43.7%)  1666 (87.0%) | 3816 (41.1%)  4990 (53.8%) | 836 (42.2%)  1728 (87.3%) | 1140 (37.4%)  1485 (48.8%) | 917 (40.1%)  1952 (85.3%) | 1078 (27.6%)  1294 (33.1%) | 196 (35.8%)  384 (70.1%) | 6345 (50.2%)  8274 (65.4%) | 5119 (50.7%)  9078 (89.9%) |
| **Fasting glycemia**  before exposure  during exposure | 1704 (17.4%)  2097 (21.4%) | 439 (22.9%)  1174 (61.3%) | 1821 (19.6%)  2345 (25.3%) | 402 (20.3%)  1204 (60.8%) | 631 (20.7%)  681 (22.4%) | 473 (20.7%)  1282 (56.0%) | 551 (14.1%)  618 (15.8%) | 91 (16.6%)  252 (46.0%) | 4563 (36.1%)  4620 (36.5%) | 3646 (36.1%)  6902 (68.3%) |
| **Kalemia**  before exposure  during exposure | 2423 (14.7%)  2836 (28.9%) | 642 (33.5%)  1433 (74.8%) | 2616 (28.2%)  3312 (35.7%) | 647 (32.7%)  1473 (74.4%) | 1501 (49.3%)  1672 (54.9%) | 1075 (47.0%)  1935 (84.5%) | 1396 (35.7%)  1530 (39.1%) | 166 (30.3%)  386 (70.4%) | 7129 (56.4%)  6094 (48.2%) | 5785 (57.3%)  8044 (79.7%) |
| **Lipids**  before exposure  during exposure | 3193 (32.6%)  1494 (15.2%) | 675 (35.3%)  1041 (54.4%) | 3830 (41.3%)  1787 (19.3%) | 732 (37.0%)  1045 (52.8%) | 996 (32.7%)  544 (17.9%) | 707 (30.9%)  1120 (48.9%) | 681 (17.4%)  351 (9.0%) | 116 (21.2%)  184 (33.6%) | 6192 (49.0%)  3336 (26.4%) | 4829 (47.8%)  5784 (57.3%) |
| **DXA-scan**  before exposure  during exposure | 986 (10.1%)  389 (4.0%) | 231 (12.1%)  447 (23.3%) | 920 (9.9%)  369 (4.0%) | 220 (11.1%)  376 (19.0%) | 439 (14.4%)  236 (7.8%) | 362 (15.8%)  577 (25.2%) | 385 (9.9%)  196 (5.0%) | 51 (9.3%)  116 (21.2%) | 1998 (15.8%)  918 (7.3%) | 1713 (17.0%)  2225 (22.0%) |
| **Eye survey**  before exposure  during exposure | 1053 (10.7%)  373 (3.8%) | 229 (12.0%)  432 (22.6%) | 1273 (13.7%)  446 (4.8%) | 265 (13.4%)  479 (24.2%) | 277 (9.1%)  149 (4.9%) | 193 (8.4%)  475 (20.8%) | 218 (5.6%)  72 (1.8%) | 43 (7.9%)  87 (15.9%) | 2029 (16.1%)  1192 (9.4%) | 1536 (15.2%)  2480 (24.6%) |
| **Flu vaccine**  before exposure  during exposure | 6410 (65.4%)  2825 (28.8%) | 1264 (66.0%)  1639 (85.6%) | 7306 (78.8%)  3132 (33.8%) | 1484 (75.0%)  1772 (89.5%) | 1393 (45.7%)  996 (32.7%) | 1077 (47.1%)  1746 (76.3%) | 981 (25.1%)  632 (16.2%) | 177 (32.3%)  322 (58.8%) | 8359 (66.1%)  5167 (40.9%) | 6769 (67.0%)  8177 (81.0%) |
| **Pneumococcal vaccine**  before exposure  during exposure\* | 5198 (53.0%)  263 (5.7%) | 1120 (58.5%)  244 (30.7%) | 6805 (73.4%)  245 (9.9%) | 1397 (70.6%)  215 (36.9%) | 994 (32.6%)  139 (6.8%) | 784 (34.3%)  492 (32.7%) | 567 (14.5%)  87 (2.6%) | 118 (21.5%)  78 (18.1%) | 6548 (51.8%)  442 (7.3%) | 5311 (52.6%)  4788 (29.6%) |

\* the patients vaccinated before glucocorticoid initiation were excluded